StephenLaneRicheyMDMPH, FACP

Oncology • Fort Worth, TX

Hematology Oncology Consultant Phase I Research Fort Worth, US Oncology Translational Research Program

Join to view full profile

Dr. Richey is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Richey's full profile

Already have an account?

Office
500 S Henderson St
Ste 200
Fort Worth, TX 76104
Phone+1 817-413-1500

Fax+1 817-413-1499
Is this information wrong?

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 2004 - 2007
Louisiana State University School of Medicine in New OrleansClass of 2004

Certifications & Licensure

TX State Medical License 2007 - 2024
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Start of enrollment: 2011 Apr 01
Completed
Phase 1, Phase 2
A Study of BBI503 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2012 Feb 01
Completed
Phase 1
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer Start of enrollment: 2013 Sep 09
Terminated
Phase 1
Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients Start of enrollment: 2013 Oct 01
Terminated
Phase 1
Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias Start of enrollment: 2018 Oct 29
Terminated
Phase 1
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer Start of enrollment: 2019 Apr 01
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

2 citations
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients wit...
, , , , , , , , , , , , , , , > ;Breast Cancer Research and Treatment. 2019 Jul 31
41 citations
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.
Martin H. Voss, Arif Hussain, Nicholas J. Vogelzang, J.-L. Lee, Bhumsuk Keam, Sun Young Rha, Ulka N. Vaishampayan, W. B. Harris, Stephen Lane Richey, J. M. Randall, Da...> ;Annals of Oncology. 2017 Nov 1
22 citations
A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma
Sumanta K. Pal, Arun Azad, Shailender Bhatia, Harry A. Drabkin, Brian A. Costello, John Sarantopoulos, Ravindran Kanesvaran, Richard C. Lauer, Alexander Starodub, Ralp...> ;Clinical Cancer Research. 2015 Aug 1
5 citations
Angiopoietins and non-vascular endothelial growth factor antiangiogenic targets in advanced renal cell carcinoma.
Stephen Lane Richey, Thomas E. Hutson> ;Cancer Journal. 2013 Jul 1
5 citations
Phase II Trial of Pemetrexed Plus Gemcitabine in Patients With Locally Advanced and Metastatic Nonclear Cell Renal Cell Carcinoma
S. L. Richey, Pheroze Tamboli, Chaan S. Ng, E. Lin, Zita D. Lim, John C. Araujo, Eric Jonasch, Padmanee Sharma, Lance C. Pagliaro, Nizar M. Tannir> ;American Journal of Clinical Oncology. 2013 Oct 1
8 citations
Metastatic extraosseous Ewing's sarcoma (EES)/primitive neuroectodermal tumor (PNET) of the kidney: 8-year durable response after induction and maintenance chemotherapy.
S. L. Richey, Priya Rao, Christopher G. Wood, Shreyaskumar Patel, Nizar M. Tannir> ;Clinical Genitourinary Cancer. 2012 Sep 1
17 citations
Durable Remission of Metastatic Renal Cell Carcinoma With Gemcitabine and Capecitabine After Failure of Targeted Therapy
S. L. Richey, Chaan S. Ng, Zita D. Lim, Eric Jonasch, Nizar M. Tannir> ;Journal of Clinical Oncology. 2011 Mar 10
Long-term survival of patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN).
Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Tamboli P, Patel K, Matin SF, Tannir NM> ;J. Clin. Oncol.. 2011-03-01
Outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with systemic therapy without cytoreductive nephrectomy (CN).
Richey SL, Culp SH, Wood CG, Corn PG, Jonasch E, Tannir NM> ;J. Clin. Oncol.. 2009-05-20
Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor.
Vogelzang NJ, Hutson TE, Samlowski W, Somer B, Richey S, Alemany C, Loesch D, Richards P, Gardner L, Sportelli P> ;J. Clin. Oncol.. 2009-05-20
23 citations
Tourniquets for the control of traumatic hemorrhage: a review of the literature
Stephen L Richey> ;World Journal of Emergency Surgery. 2007 Oct 24
29 citations
Development and validation of a multiplexed Y-chromosome STR genotyping system, Y-PLEX 6, for forensic casework.
Sudhir K. Sinha, Bruce Budowle, Santosh S. Arcot, Stephen L. Richey, Ranajit Chakraborty, Mary D. Jones, Patrick W. Wojtkiewicz, Dolores A. Schoenbauer, Ann Marie Gros...> ;Journal of Forensic Sciences. 2003 Jan 1
1 citations
Detection and correction of a migration anomaly on a 310 genetic analyzer.
Jaiprakash G. Shewale, Stephen L. Richey, Sudhir K. Sinha> ;Journal of Forensic Sciences. 2000 Nov 1
Reply to Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies?
S. L. Richey, Stephen H. Culp, Eric Jonasch, Surena F. Matin, Christopher G. Wood, Nizar M. Tannir> ;Annals of Oncology. 2011 May 1
49 citations
Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy
S. L. Richey, Stephen H. Culp, Eric Jonasch, Paul G. Corn, Lance C. Pagliaro, Pheroze Tamboli, K. K. Patel, Surena F. Matin, Christopher G. Wood, Nizar M. Tannir> ;Annals of Oncology. 2011 May 1
Join now to see all

Professional Memberships

American College of Physicians - ACP
Member

Hospital Affiliations

Baylor Scott & White All Saints Medical Center - Fort WorthFort Worth, Texas
Texas Health Harris Methodist Hospital Fort WorthFort Worth, Texas
Medical City Fort WorthFort Worth, Texas